IBC to Hold Inaugural High-Content Analysis Conference
IBC Life Sciences will hold its first annual conference on high-content analysis Nov. 17-18 in Washington, DC, the company said last week.
The conference will feature discussions and presentations about "how to effectively utilize high-content cellular analysis for screening and go/no-go decision making," IBC said, including case studies from Eli Lilly and Wyeth, and presentations from James Inglese of the NIH Chemical Genomics Center and Ralph Garippa of Hoffman-La Roche.
Additional information about the conference can be found here: http://www.ibclifesciences.com/3144.
Protedyne Completes $10M Series D Financing Round
Protedyne said last week that it has raised a total of $10 million in a Series D round of financing.
Investors included investment bank and new participant Allen & Company, as well as existing investors The Sprout Group, Meridian Venture Partners, Long River Ventures, Village Venture Partners, and Boston Community Venture Funds, Protedyne said.
Qiagen had also previously participated in the Series D financing, the company said.
Protedyne plans to use the proceeds for working capital purposes, including enhancements to its BioCube laboratory automation product.
Galapagos Signs Huntington Disease Research Deal with High Q Foundation
Galapagos said recently that it has signed a two-year target-discovery agreement with the High Q Foundation, a non-profit organization that supports Huntington disease research.
High Q and Galadeno, Galapagos' partnering unit, will use Galapagos' adenoviral siRNA and cDNA collections to discover and validate drug targets for the development of new Huntington disease therapies.
Galapagos said that it could ultimately receive up to $3 million from the High Q Foundation for the project. The company also has the option to develop certain targets identified in the program.
Galapagos said that the final agreement with High Q has not yet been signed, but that it expects to do so before Oct. 1.